Partial Response to Crizotinib in a Lung Adenocarcinoma Patient with a Novel FBXO11 (Intergenic)-ALK (Exon 20-29)

Jing He1, Youyuan Yao1, Fei Quan2

  • 1Medical Oncology Department, Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, People's Republic of China.

PubMed

Insights

Detecting intergenic-gene fusions like FBXO11-ALK in lung cancer requires RNA-seq for accurate drug selection. This case highlights RNA-seq

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Intergenic-gene fusions detected by DNA sequencing can complicate targeted therapy selection due to unknown intergenic region functions.
  • Anaplastic Lymphoma Kinase (ALK) rearrangements are key drivers in a subset of lung adenocarcinomas.